Antibody levels (Mean ± SD) | Patients with schizophrenia spectrum disorders (n = 100)* | IIH Controls (n = 39)* | p-value |
---|---|---|---|
EBV | n = 84 (84%) | n = 37 (95%) | Chi2 = 2.942 p = 0.086 |
 Serum (U) | 51,574.59 ± 50,164.67 | 54,007.71 ± 47,090.30 | z = − 0.602 p = 0.547 |
 CSF (U) | 120.73 ± 155.75 | 79.02 ± 81.99 | z = − 0.875 p = 0.382 |
 CSF/Serum | 2.81 ± 4.19 | 1.57 ± 0.84 | z = − 2.768 p = 0.006 |
 AI | 0.93 ± 0.82 | 0.80 ± 0.29 | z = − 0.535 p = 0.593 |
CMV | n = 41 (41%) | n = 15 (39%) | Chi2 = 0.075 p = 0.784 |
 Serum (U) | 27,638.94 ± 27,336.05 | 33,900.25 ± 33,022.25 | z = − 0.916 p = 0.360 |
 CSF (U) | 64.14 ± 55.43 | 66.55 ± 77.03 | z = − 0.139 p = 0.890 |
 CSF/Serum | 2.64 ± 1.05 | 2.16 ± 1.69 | z = − 2.470 p = 0.014 |
 AI | 1.16 ± 0.47 | 1.11 ± 0.69 | z = − 1.018 p = 0.309 |
HSV1/2 | n = 59 (59%) | n = 26 (67%) | Chi2 = 0.694 p = 0.405 |
 Serum (U) | 62,392.74 ± 33,027.48 | 70,727.88 ± 44,320.81 | z = − 0.019 p = 0.985 |
 CSF (U) | 160.16 ± 197.33 | 155.11 ± 130.48 | z = − 0.048 p = 0.962 |
 CSF/Serum | 2.77 ± 3.93 | 2.17 ± 1.52 | z = − 0.992 p = 0.321 |
 AI | 0.96 ± 0.45 | 1.01 ± 0.50 | z = − 0.105 p = 0.916 |
T. gondii | n = 17 (17%) | n = 16 (41%) | Chi2 = 8.946 p = 0.003 |
 Serum (U) | 21,313.23 ± 13,672.51 | 27,006.46 ± 14,736.33 | z = − 1.513 p = 0.136 |
 CSF (U) | 47.60 ± 42.40 | 64.54 ± 39.71 | z = − 1.693 p = 0.094 |
 CSF/Serum | 2.31 ± 1.29 | 4.33 ± 6.46 | z = − 0.036 p = 0.986 |
 AI | 0.86 ± 0.27 | 2. 91 ± 3.40 | z = − 1.549 p = 0.127 |